ArticleThe Journal of investigative dermatology2003
Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes.
Article in The Journal of investigative dermatology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides.American journal of physiology. Cell physiology · 2022Review
- Roles Played by Stress-Induced Pathways in Driving Ethnic Heterogeneity for Inflammatory Skin Diseases.Frontiers in immunology · 2022Review
- Stress-related skin disorders.Reviews in endocrine & metabolic disorders · 2016Review
- Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin.PloS one · 2014Article
- Key role of CRF in the skin stress response system.Endocrine reviews · 2013Review
- Neuroendocrinology of the skin: An overview and selective analysis.Dermato-endocrinology · 2011Article
- 20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes.Journal of cellular physiology · 2010Article
- Emerging role of alternative splicing of CRF1 receptor in CRF signaling.Acta biochimica Polonica · 2010Review
- Article
- CRH inhibits NF-kappa B signaling in human melanocytes.Peptides · 2006Article
- Corticotropin releasing hormone and the skin.Frontiers in bioscience : a journal and virtual library · 2006Review
- Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.CNS & neurological disorders drug targets · 2006Review
- CRH functions as a growth factor/cytokine in the skin.Journal of cellular physiology · 2006Article
- Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes.The British journal of dermatology · 2005Article
- Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes.The Journal of endocrinology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Treatment of human HaCaT keratinocytes with corticotropin-releasing hormone modulates cell proliferation and expression of inflammation markers. In this study we report that corticotropin-releasing hormone also inhibits nuclear factor-kappaB binding and transcriptional activity. Incubating cells in the absence of growth factors increased nuclear factor-kappaB activity; this effect was significantly attenuated by corticotropin-releasing hormone. Specifically, corticotropin-releasing hormone downregulated p50/p50 and p50/p65 dimers of nuclear factor-kappaB, diminished kappaB-driven CAT reporter gene activity and inhibited IkappaB-beta degradation. Moreover, corticotropin-releasing hormone inhibited the trans-cription of the nuclear factor-kappaB responsive genes, interleukin-2 and heat shock protein 90.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.